A quality improvement strategy can improve electronic health record-based screening for depression and anxiety in people with epilepsy.

The FDA has approved Brekiya (dihydroergotamine mesylate) injection for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.

The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...